Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Imiquimod - 3M Pharmaceuticals

Next Previous
Drug Profile

Imiquimod - 3M Pharmaceuticals

Alternative Names: Aldara; Beselna Cream 5%; DZ 2636; MTD-39; R 837; S 26308; Vyloma; Zyclara

Latest Information Update: 04 Nov 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator 3M Pharmaceuticals
  • Developer 3M Pharmaceuticals; Maastricht University; Meda; Medicis Pharmaceutical Corporation; Mochida Pharmaceutical
  • Class Adjuvants; Aminoquinolines; Antineoplastics; Antivirals; Skin disorder therapies; Small molecules
  • Mechanism of Action Immunostimulants; Toll-like receptor 7 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Actinic keratosis; Basal cell cancer; Genital warts; Herpes simplex virus infections
  • No development reported Cervical intraepithelial neoplasia; Molluscum contagiosum; Photodamage; Tinea pedis; Vulvar intraepithelial neoplasia
  • Discontinued Hepatitis B; Hepatitis C; HIV infections; Warts

Most Recent Events

  • 20 May 2021 Launched for Actinic keratosis in Czech Republic, Denmark, Sweden, Spain, Switzerland, Ireland, Finland, Norway, Netherlands, Austria (Topical, Cream 3.7%)
  • 20 May 2021 Launched for Actinic keratosis in Norway, Netherlands, Switzerland, Ireland, Germany, Spain, Finland, Sweden, Denmark, Germany (Topical, Cream 2.5%)
  • 20 May 2021 Launched for Basal cell cancer in Norway, Netherlands, Swaziland, Swaziland, Germany, Ireland, Spain, Finland, Sweden, Denmark, Austria, Czech Republic (Topical)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top